Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Purchases 5,507 Shares of STERIS plc (NYSE:STE)

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of STERIS plc (NYSE:STEGet Rating) by 13.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,091 shares of the medical equipment provider’s stock after buying an additional 5,507 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in STERIS were worth $11,423,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Assetmark Inc. boosted its stake in shares of STERIS by 1,272.7% during the 3rd quarter. Assetmark Inc. now owns 151 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 140 shares during the last quarter. MD Financial Management Inc. boosted its stake in shares of STERIS by 100.0% during the 3rd quarter. MD Financial Management Inc. now owns 210 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 105 shares during the last quarter. Destiny Wealth Partners LLC acquired a new position in shares of STERIS during the 4th quarter worth about $64,000. AdvisorNet Financial Inc lifted its stake in STERIS by 34.3% in the 4th quarter. AdvisorNet Financial Inc now owns 309 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 79 shares during the last quarter. Finally, Arlington Partners LLC acquired a new stake in STERIS in the 4th quarter valued at about $108,000. Institutional investors own 89.98% of the company’s stock.

Several brokerages recently issued reports on STE. StockNews.com began coverage on shares of STERIS in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Wolfe Research began coverage on shares of STERIS in a research note on Tuesday, April 5th. They issued an “outperform” rating and a $275.00 target price for the company. Needham & Company LLC raised their target price on shares of STERIS from $254.00 to $263.00 and gave the company a “buy” rating in a research note on Thursday, February 10th. Finally, JMP Securities raised their target price on shares of STERIS from $250.00 to $270.00 and gave the company a “market outperform” rating in a research note on Monday, February 14th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, STERIS has an average rating of “Buy” and an average target price of $261.14.

STERIS stock opened at $233.45 on Friday. The stock has a market cap of $23.37 billion, a P/E ratio of 80.78 and a beta of 0.64. The company has a quick ratio of 1.47, a current ratio of 2.13 and a debt-to-equity ratio of 0.48. STERIS plc has a twelve month low of $188.10 and a twelve month high of $255.93. The company’s 50-day moving average price is $237.30 and its two-hundred day moving average price is $232.50.

STERIS (NYSE:STEGet Rating) last released its quarterly earnings results on Tuesday, February 8th. The medical equipment provider reported $2.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.17. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.20 billion. STERIS had a net margin of 6.57% and a return on equity of 12.08%. The business’s revenue was up 48.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.73 EPS. Equities analysts anticipate that STERIS plc will post 7.89 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 24th. Stockholders of record on Friday, February 25th were issued a dividend of $0.43 per share. The ex-dividend date was Thursday, February 24th. This represents a $1.72 annualized dividend and a dividend yield of 0.74%. STERIS’s dividend payout ratio is presently 59.52%.

In related news, Director Cynthia L. Feldmann sold 1,891 shares of STERIS stock in a transaction that occurred on Thursday, February 10th. The shares were sold at an average price of $234.10, for a total value of $442,683.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Karen L. Burton sold 2,600 shares of STERIS stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $232.61, for a total transaction of $604,786.00. The disclosure for this sale can be found here. Insiders have sold 24,491 shares of company stock worth $6,075,309 over the last ninety days. Insiders own 1.14% of the company’s stock.

About STERIS (Get Rating)

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Read More

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEGet Rating).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.